An oligodeoxynucleotide capable of lessening acute lung inflammatory injury in mice infected by influenza virus

被引:20
作者
Fang, Mingli [1 ]
Wan, Min [1 ]
Guo, Sheng [1 ]
Sun, Ran [3 ]
Yang, Ming [2 ]
Zhao, TieSuo [2 ]
Yan, Youyou [2 ]
Zhang, Yongsheng [1 ]
Huang, Wenhui [1 ]
Wu, Xiuli [1 ]
Yu, Yongli [2 ]
Wang, Liying [1 ]
Hua, Shucheng [4 ]
机构
[1] Jilin Univ, Norman Bethune Coll Med, Dept Mol Biol, Changchun 130021, Peoples R China
[2] Jilin Univ, Norman Bethune Coll Med, Dept Immunol, Changchun 130021, Peoples R China
[3] Jilin Univ, Tissue Bank, China Japan Union Hospital, Changchun 130021, Peoples R China
[4] Jilin Univ, Hosp 1, Dept Resp Med, Changchun 130021, Peoples R China
关键词
Influenza virus; Infection; Acute lung inflammatory injury; Oligodeoxynucleotide; Therapy; TNF; INHIBITION; IMMUNE; TLR7; INTERFERENCE; ACTIVATION; RECEPTORS; APOPTOSIS; RESPONSES; SEVERITY;
D O I
10.1016/j.bbrc.2011.10.062
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Infection of influenza virus could induce acute lung inflammatory injury (ALII) that was at least partially caused by excessive innate immune responses. To study whether down-regulating Toll-like receptor (TLR)-mediated innate immune response could lessen influenza virus-induced ALII, a microsatellite DNA mimicking oligodeoxynucleotide (MS ODN), named as SATO5f capable of inhibiting TLR7/9-activation in vitro, was used to treat mice infected with FM1 virus. In parallel, two MS ODNs confirmed with less or no in vitro activities, named as MS19 and MS33, were used as controls. Unexpectedly, SATO5f failed to lessen ALII in the mice, whereas MS19 significantly inhibited the weight loss and displayed dramatic effect on lessening the ALII by reducing consolidation, hemorrhage, intra-alveolar edema and neutrophils infiltration in lungs of the mice. Meanwhile. MS19 could decrease the mortality of influenza virus infected mice and down-regulate TNE-alpha production in their lungs. The data suggest that MS19 might display its therapeutic role on ALII induced by influenza virus by reducing over-production of TINIF-alpha. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:342 / 347
页数:6
相关论文
共 36 条
[1]  
Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
[2]   Production of type I interferons: plasmacytoid dendritic cells and beyond [J].
Asselin-Paturel, C ;
Trinchieri, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :461-465
[3]   Treatment of lupus-prone of TLR7 and TLR9 leads to mice with a dual inhibitor reduction of autoantibody production and amelioration of disease symptoms [J].
Barrat, Franck J. ;
Meeker, Thea ;
Chan, Jean H. ;
Guiducci, Cristiana ;
Cofftnan, Robert L. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (12) :3582-3586
[4]   How TNF was recognized as a key mechanism of disease [J].
Clark, Ian A. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2007, 18 (3-4) :335-343
[5]   Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment [J].
Fritz, RS ;
Hayden, FG ;
Calfee, DP ;
Cass, LMR ;
Peng, AW ;
Alvord, WG ;
Strober, W ;
Straus, SE .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :586-593
[6]   Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod [J].
Gibson, SJ ;
Lindh, JM ;
Riter, TR ;
Gleason, RM ;
Rogers, LM ;
Fuller, AE ;
Oesterich, JL ;
Gorden, KB ;
Qiu, XH ;
McKane, SW ;
Noelle, RJ ;
Miller, RL ;
Kedl, RM ;
Fitzgerald-Bocarsly, P ;
Tomai, MA ;
Vasilakos, JP .
CELLULAR IMMUNOLOGY, 2002, 218 (1-2) :74-86
[7]   IN-VITRO INHIBITION OF MURINE IFN-GAMMA PRODUCTION BY PHOSPHOROTHIOATE DEOXYGUANOSINE OLIGOMERS [J].
HALPERN, MD ;
PISETSKY, DS .
IMMUNOPHARMACOLOGY, 1995, 29 (01) :47-52
[8]   Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells [J].
Hu, Dali ;
Su, Xuejin ;
Sun, Ran ;
Yang, Guang ;
Wang, Huaying ;
Rena, Jiling ;
Sun, Luguo ;
Wu, Xiuli ;
Hu, Xiaoping ;
Yu, Yongli ;
Wang, Liying .
MOLECULAR IMMUNOLOGY, 2009, 46 (07) :1387-1396
[9]  
Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO
[10]  
2-L